| Date | Title | Description |
| 15.05.2024 | Positive Q1 Results Posted After Clinical Trial Delivers Statistically-Significant Data for Bipolar: NRx: Nasdaq: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Statistically-Significant Data Supports NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) in Clinical Trial
NRx Pharmaceuticals,... |
| 06.05.2024 | Results Show Superior Safety & Efficacy for NRX-101; Accelerated FDA Approval sought for Bipolar Depression: NASDAQ NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
NRx Pharmaceuticals Reports Promising Results: Akathisia Reduction and Accelerated Approval Plans : NRx Pharmaceuticals... |
| 06.05.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression | Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified anal... |
| 30.04.2024 | Oral Antidepressants for Reduction in Suicidality Could Deliver New Standard of Care for Bipolar Depression: NASDAQ NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Revolutionizing Bipolar Depression Treatment: The Potential of Oral Antidepressants: NRx Pharmaceuticals, Inc. (Nasdaq:... |
| 18.04.2024 | NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement | The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter
Four upcoming milestones expected: data from trials in Suicidal Bipolar Depression and Chronic Pain, N... |
| 18.04.2024 | NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock | RADNOR, Pa., April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten ... |
| 17.04.2024 | New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous & Subcutaneous Use NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
NRx Pharmaceuticals Unveils New Data on Infection Avoidance and pH Neutral Ketamine Development: (Nasdaq: NRXP)
NRx Pha... |
| 15.04.2024 | Development of pH Neutral Ketamine ; Trials Progressing for Suicide Drug Treatment with Strong Q4 Results: NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Strong Q4 Results Propel NRx Pharmaceuticals' pH Neutral Ketamine Development Amid Approved Stock Dividend: NRXP
NRx Ph... |
| 08.04.2024 | Data Lock Achieved in Trials for Suicidal Treatment; Strong Q4; Approved Stock Dividend & Share Reduction Nasdaq: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Data Lock Achieved in Latest Clinical Trials for Suicidal Treatment After Strong Q4 Results with Approved Stock Dividen... |
| 01.04.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per... |
| 19.03.2024 | Planned Public Stock Dividend, Royalty Rights Pledged to Shareholders for Valuable Ketamine Franchise: NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Planned Public Stock Dividend Announced by Hope Therapeutics: : NRx Pharmaceuticals (Nasdaq: NRXP)
NRx Pharmaceuticals,... |
| 18.03.2024 | NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders | NRx Pharmaceuticals Board of Directors has authorized its Chairman, CEO, and management to take all necessary steps to affect the Dividend and Royalty Rights to NRXP Shareholders and applicable warrant holders
Dividend is intended to distri... |
| 12.03.2024 | Aggressive Actions to Counter Naked Shorting & Protect Shareholder Value; Pioneering Mental Health Issues: NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
NRx Pharmaceuticals (Nasdaq: NRXP): Pioneering Drug Development in Mental Health and Chronic Pain Treatment
NRx Pharmac... |
| 11.03.2024 | Planned Shipment of IV Ketamine to 100+ US Pharmacies; Potential of $330 Million in Payments & Royalties: NASDAQ; NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Trial Endpoint for Revolutionary Suicidal Bipolar Depression, Chronic Pain, and PTSD Drug: NRx Pharmaceuticals (Nasdaq:... |
| 04.03.2024 | Trial Endpoint for 1st Suicidal Bipolar, PTSD & Pain Drug: Partners Can Provide $329 Million + Royalties: Nasdaq: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
NRx Pharmaceuticals Hits Milestone in Suicidal Bipolar Depression Treatment; Potential $329 Million Deal with Partners:... |
| 20.02.2024 | Share Dividend Announcement to Counter Short Selling at Upcoming Conference: NRx Pharmaceuticals (Nasdaq: NRXP) | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
NRx Pharmaceuticals: Advancements and Initiatives Overview
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
NRx aims to provide ... |
| 12.02.2024 | NRx Secures $5 Million Milestone Payment for Development of New Suicidal Bipolar Depression Treatments: (Nasdaq: NRXP) | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Advancing Treatment for Suicidal Bipolar Depression: NRx Pharmaceuticals, Inc. Receives $5 Million Milestone Payment. N... |
| 08.02.2024 | Biopharma Company Focused on Breakthrough Medicines for Suicidal Bipolar Depression, Chronic Pain & PTSD: NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Breakthrough Medicines for Suicidal Bipolar Depression, Chronic Pain & PTSD: NASDAQ: NRXP $NRXP
NRx Pharmaceuticals... |
| 22.08.2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation | GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / August 22, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), today announced tha... |
| 26.05.2022 | Covid-19 roundup: NRx's med gets axed from NIH trial over futility; A new drug for the pandemic enters the clinic | There were more deaths in the treatment group than placebo cohort in an NIH study of NRx Pharmaceuticals’ already-rejected Covid-19 drug, and the data safety board recommended stopping the trial.
The board said the study of... |
| 03.02.2022 | NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules | RADNOR, Pa., Feb. 2, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to mar... |
| 31.01.2022 | NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules | RADNOR, Pa., Jan. 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 sh... |
| 27.01.2022 | NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant | RADNOR, Pa., Jan. 27, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine m... |
| 18.01.2022 | NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments | ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Admi... |
| 05.01.2022 | NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treat... | RADNOR, Pa., Jan. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI® (av... |
| 03.01.2022 | NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use | RADNOR, Pa., Jan. 3, 2022 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled "Stable, Buffer-free... |
| 29.12.2021 | NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Th... | RADNOR, Pa., Dec. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients with Cri... |
| 16.11.2021 | NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results | RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will ... |
| 05.11.2021 | NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Produ... | RADNOR, Pa., Nov. 5, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the Economy in preparatio... |
| 05.11.2021 | US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure | RADNOR, Pa., Nov. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company (NRx), today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorizat... |
| 02.11.2021 | NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 | RADNOR, Pa., Nov. 2, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which is being tested in the ACTIV-3b Critical Care Phase... |
| 14.10.2021 | NRx Pharmaceuticals : Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure | RADNOR, Pa., Oct. 14, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of resp... |
| 12.10.2021 | NRx Pharmaceuticals : Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil) | RADNOR, Pa., Oct. 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration ... |
| 29.09.2021 | NRx Pharmaceuticals : Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 | RADNOR, Pa., Sept. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3b Critical Care Pha... |
| 27.09.2021 | NRx Pharmaceuticals : Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) | RADNOR, Pa., Sept. 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19... |
| 08.09.2021 | NRx Pharmaceuticals : to Participate in H.C. Wainwright 23rd Annual Global Investment Conference | RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference S... |
| 30.08.2021 | NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 | |
| 30.08.2021 | NRx Pharmaceuticals : Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 | RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Fai... |
| 26.08.2021 | NRx Pharmaceuticals : to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies | RADNOR, Pa., Aug. 26, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency U... |
| 24.08.2021 | NRx Pharmaceuticals : Announces Closing of $30 Million Private Placement | RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the ... |
| 23.08.2021 | NRx Pharmaceuticals : Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary | RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the highe... |
| 19.08.2021 | NRx Pharmaceuticals : Announces $30 Million Private Placement | RADNOR, Pa., Aug. 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 sh... |
| 18.08.2021 | NRx Pharmaceuticals : Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 | RADNOR, Pa., Aug. 18, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase... |
| 17.08.2021 | NRx Pharmaceuticals : Announces 2nd Quarter 2021 Financial Update | RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conf... |
| 16.08.2021 | NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update | |
| 10.08.2021 | NRx Pharmaceuticals : to Ring Nasdaq Closing Bell on August 10, 2021 | RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx,... |
| 09.08.2021 | NRx Pharmaceuticals : Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia | RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID... |
| 09.08.2021 | NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia | |
| 04.08.2021 | NRx Pharmaceuticals : Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions | RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human V... |
| 27.07.2021 | NRx Pharmaceuticals : Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia | RADNOR, Pa., July 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emerg... |
| 22.07.2021 | NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Appr... | |
| 22.07.2021 | NRx Pharmaceuticals : Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Ap... | RADNOR, Pa., July 22, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an... |
| 12.07.2021 | NRx Pharmaceuticals : Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine | TEL AVIV, Israel and RADNOR, Pa., July 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company announced today that it has signed a Memorandum Of Understanding with the Government of Israel to li... |
| 06.07.2021 | NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia | |
| 06.07.2021 | NRx Pharmaceuticals : Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia | RADNOR, Pa., July 6, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage biopharmaceutical company, today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of ... |
| 15.06.2021 | NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol | |
| 15.06.2021 | NRX PHARMACEUTICALS, INC.
NRx Pharmaceuticals : Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol | RADNOR, Pa., June 15, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company, today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP). Overall, patients receiving ... |
| 28.04.2021 | BIG ROCK PARTNERS ACQUISITION CORP.
NeuroRx : and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia | RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Pro... |
| 06.04.2021 | RELIEF THERAPEUTICS HOLDING AG
NeuroRx : Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir | RADNOR, Pa., April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multi... |
| 29.03.2021 | RELIEF THERAPEUTICS HOLDING AG
Relief Therapeutics : C O R R E C T I O N -- NeuroRx/ | In the news release, NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19, issued 29-Mar-2021 by NeuroRx over... |
| 26.03.2021 | NeuroRx : Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure | RADNOR, Pa., March 26, 2021 /PRNewswire/ -- NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for... |
